10-(3,5-Diacetylanilino)-10-oxodecanoic acid | 489476-21-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 10-(3,5-Diacetylanilino)-10-oxodecanoic acid
• CAS: 489476-21-3
• 化学式: C₂₀H₂₇NO₅
• 分子量: 361.4
• InChiKey: RONHYDSOWOYGOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING
  申请人：SIELECKI-DZURDZ M. THAIS

  公开号：US20080070959A1

  公开（公告）日：2008-03-20

  The present invention relates to compounds having the formula: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.
• US7291647B2
  申请人：——

  公开号：US7291647B2

  公开（公告）日：2007-11-06
• US7863334B2
  申请人：——

  公开号：US7863334B2

  公开（公告）日：2011-01-04
• US8247455B2
  申请人：——

  公开号：US8247455B2

  公开（公告）日：2012-08-21
• [EN] AROMATIC GUANYLHYDRAZONES AS EFFECTIVE COMPOUNDS AGAINST NEURODISEASES<br/>[FR] GUANYLHYDRAZONES AROMATIQUES UTILISES COMME COMPOSES EFFICACES CONTRE LES MALADIES NERVEUSES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2003006426A1

  公开（公告）日：2003-01-23

  The present invention provides novel aromatic guanylhydrazone compounds and relates to the use of a class of aromatic guanylhydrazones compounds as pharmaceutically active agents, especially for the prophylaxis and/or treatment of neurodiseases such as addiction, alzheimer's disease, anxiety disorders, autism, blindness, cerebral palsy, chronic fatigue syndrome, Chorea Huntington, depression, dyslexia, epilepsy, infectious diseases, prion diseases, prion infections, multiple sclerosis, muscular dystrophy, neurology, neurotoxicities, pain, parkinson's disease, schizophrenia, sleep disorders, stress, stroke, tourette syndrome, and tumors. Furthermore, the present invention relates to pharmaceutical compositions containing at least one aromatic guanylhydrazone compound and/or pharmaceutically acceptable salt thereof. These pharmaceutical compositions can be used within methods for preventing and/or treating neurological and/or mental diseases, especially prion infections and prion diseases.